Grafanaki K, Bania A, Kaliatsi EG, Vryzaki E, Vasilopoulos Y, Georgiou S. The imprint of exposome on the development of atopic dermatitis across the lifespan: a narrative review. J Clin Med. 2023;12:2180.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Augustin M, Misery L, von Kobyletzki L, Armario-Hita JC, Mealing S, Redding M. Unveiling the true costs and societal impacts of moderate-to-severe atopic dermatitis in Europe. J Eur Acad Dermatol Venereol. 2022;36:3–16.

Article  PubMed  Google Scholar 

Wolkerstorfer A, Strobos MA, Glazenburg EJ, Mulder PG, Oranje AP. Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis. J Am Acad Dermatol. 1998;39:226–31.

Zuberbier T, Orlow SJ, Paller AS, Taïeb A, Allen R, Hernanz-Hermosa JM, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol. 2006;118:226–32.

Article  PubMed  Google Scholar 

Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema—part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36:1904–26.

Article  PubMed  CAS  Google Scholar 

Mooney E, Rademaker M, Dailey R, Daniel BS, Drummond C, Fischer G, et al. Adverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement. Australas J Dermatol. 2015;56:241–51.

Article  PubMed  Google Scholar 

Eichenfield LF, Luger T, Papp K, Silverberg JI, Sierka D, Zang C, et al. Topical agents for the treatment of atopic dermatitis. J Drugs Dermatol. 2020;19:50–64.

Article  PubMed  CAS  Google Scholar 

Arana A, Pottegård A, Kuiper JG, Booth H, Reutfors J, Calingaert B, et al. Long-term risk of skin cancer and lymphoma in users of topical tacrolimus and pimecrolimus: final results from the extension of the cohort study protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE). Clin Epidemiol. 2021;13:1141–53.

Article  PubMed  PubMed Central  Google Scholar 

Schick MA, Schlegel N. Clinical implication of phosphodiesterase-4-inhibition. Int J Mol Sci. 2022;23:1209.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hoy SM. Crisaborole ointment 2%: a review in mild to moderate atopic dermatitis. Am J Clin Dermatol. 2017;18:837–43.

Article  PubMed  Google Scholar 

Eichenfield LF, Gower RG, Xu J, Alam MS, Su JC, Myers DE, et al. Once-daily crisaborole ointment, 2%, as a long-term maintenance treatment in patients aged ≥ 3 months with mild-to-moderate atopic dermatitis: a 52-week clinical study. Am J Clin Dermatol. 2023;24:623–35.

Article  PubMed  PubMed Central  Google Scholar 

Bissonnette R, Pavel AB, Diaz A, Werth JL, Zang C, Vranic I, et al. Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial. J Allergy Clin Immunol. 2019;144:1274–89.

Article  PubMed  CAS  Google Scholar 

Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection. J Allergy Clin Immunol Pract. 2020;8:91–101.

Article  PubMed  Google Scholar 

Lax SJ, Van Vogt E, Candy B, Steele L, Reynolds C, Stuart B, et al. Topical anti-inflammatory treatments for eczema: network meta-analysis. Cochrane Database Syst Rev. 2024;8(8):CD015064.

Wollenberg A, Werfel T, Ring J, Ott H, Gieler U, Weidinger S. Atopic dermatitis in children and adults—diagnosis and treatment. Dtsch Arztebl Int. 2023;120:224–34.

PubMed  PubMed Central  Google Scholar 

Frølunde AS, Thyssen JP, Deleuran M, Vestergaard C. Appraisal of proactive topical therapy in atopic dermatitis: pros and cons. Am J Clin Dermatol. 2021;22:775–83.

Article  PubMed  Google Scholar 

Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34:2717–44.

Article  PubMed  CAS  Google Scholar 

Sidbury R, Tom WL, Bergman JN, Cooper KD, Silverman RA, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. 2014;71:1218–33.

Atopic Dermatitis Working Group, Immunology Group, Chinese Society of Dermatology. Guideline for diagnosis and treatment of atopic dermatitis in China. Chin J Dermatol. 2020;53:81–8.

Ryan Wolf J, Chen A, Wieser J, Johnson B, Baughman L, Lee G, et al. Improved patient- and caregiver-reported outcomes distinguish tacrolimus 0.03% from crisaborole in children with atopic dermatitis. J Eur Acad Dermatol Venereol. 2024;38:1364–72.

Article  PubMed  CAS  Google Scholar 

McDowell L, Olin B. Crisaborole: a novel nonsteroidal topical treatment for atopic dermatitis. J Pharm Technol. 2019;35:172–8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Paller AS, Eichenfield LF, Kirsner RS, Shull T, Jaracz E, Simpson EL, et al. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use. Pediatrics. 2008;122:e1210–8.

Article  PubMed  Google Scholar 

Breneman D, Fleischer AB Jr, Abramovits W, Zeichner J, Gold MH, Kirsner RS, et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol. 2008;58:990–9.

Article  PubMed  Google Scholar 

Chung BY, Kim HO, Kim JH, Cho SI, Lee CH, Park CW. The proactive treatment of atopic dermatitis with tacrolimus ointment in Korean patients: a comparative study between once-weekly and thrice-weekly applications. Br J Dermatol. 2013;168:908–10.

Article  PubMed  CAS  Google Scholar 

Reitamo S, Allsopp R. Treatment with twice-weekly tacrolimus ointment in patients with moderate to severe atopic dermatitis: results from two randomized, multicentre, comparative studies. J Dermatol Treat. 2010;21:34–44.

Article  CAS  Google Scholar 

Liang Y, Liu L, Wang S, Zhao Z, Ma L, Xiang X. Efficacy and safety of 0.03% tacrolimus ointment in the long-term intermittent maintenance treatment of atopic dermatitis in children: a multicenter randomized controlled clinical trial. Chin J Dermatol. 2019;52:519–24.

Google Scholar 

Ruer-Mulard M, Aberer W, Gunstone A, Kekki OM, López Estebaranz JL, Vertruyen A, et al. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis. Pediatr Dermatol. 2009;26:551–8.

Article  PubMed  Google Scholar